The Challenges of Researching and Developing Psychedelics

This chapter explores the challenges faced by companies in the psychedelic industry, including overvaluation, difficulties in validating new drugs, and raising follow-on funding. It discusses the need for evidence of reimbursement from payers and the high costs associated with psychedelic therapies. The chapter also touches on the issues of scalability, payers recognizing the value of psychedelic therapies, and potential benefits for different types of conditions.